{"id":"W2113122060","doi":"10.1056/nejmoa1103799","title":"A Phase 3 Trial of Bevacizumab in Ovarian Cancer","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2152,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval; University of British Columbia","funders":"","keywords":"Medicine; Bevacizumab; Hazard ratio; Ovarian cancer; Internal medicine; Carboplatin; Regimen; Oncology; Progression-free survival; Interim analysis; Cancer; Confidence interval; Surgery; Randomized controlled trial; Chemotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06633579281492227,"score_gpt":0.3510873405610243,"score_spread":0.284751547746102,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}